Monitoring of antibiotic and antifungal use in healthcare facilities and long-term care facilities with an in-house pharmacy, and monitoring of bacterial resistance in healthcare facilities. Key Results for 2025
In 2025, 1,620 healthcare facilities—accounting for 83% of hospital days (HD) in France—participated in this surveillance program. Overall antibiotic use decreased by 4% compared to 2024, reaching 309 defined daily doses (DDJ) per 1,000 HD, but this decrease falls short of the target of at least a 10% reduction compared to the 2019 value (284.5 DDJ/1,000 HD). The use of antifungals, for which monitoring began in 2024, increased slightly, reaching 16 DDJ/1,000 JH, with significant variations across departments (up to 335 DDJ/ 1,000 patient-days in hematology and 129 DDJ/1,000 patient-days in intensive care). Regarding bacterial resistance, participation increased, with 1,300 participating facilities (representing 71% of patient-days in France). The incidence rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-producing Enterobacteriaceae) remained stable (0.58/1,000 patient-days), while that of carbapenemase-producing Enterobacteriaceae (CPE) continued to rise (0.041 per 1,000 inpatients), well above the target set by the SNPIA to maintain the 2019 level (0.010 per 1,000 inpatients). The incidence rate of methicillin-resistant staphylococci (MRSA) stabilized at 0.13/1,000 hospital days, within the SNPIA target (which called for a reduction of at least 10% from the 2019 value of 0.17/1,000 JH).
Author(s): Ali-Brandmeyer Olivia, Dugravot Lory, Jouzeau Amélie, Simon Loïc, Bougès Ségolène, Dumartin Catherine, Reyreaud Emmanuelle, Chabaud Aurélie, Patry Alice, D'Hollander-Pestourie Nathalie, Ploy Marie-Cécile
Publishing year: 2026
Pages: 18 p.
Collection: Monitoring Data
In relation to
Our latest news
news
Call for Nominations to Fill Vacancies on the National Reference Centers...
news
Public Health France Conference: November 9, 2026
news